Biotron Limited · ASX:BIT
Biotron — Shareholder Meeting (November 2023)
12 slides from Biotron's shareholder meeting presentation, Nov 22, 2023
Slide 1: Annual General Meeting
ANNUAL GENERAL MEETING ASX:BIT 22 November 2023 Biotron
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation may contain forward-looking statements with respect to the financial condition, results and business achievements/ performance of Biotron Limited (ACN 086 399 144) and certain of the plans and objectives of its management. These statements are ” « stateme
Slide 3: Industry-leading experts focused on transformative viral treatments
Industry-leading experts focused on transformative viral treatments @ Experienced Board & Management team with pharma, finance and VC backgrounds @ Clinical stage company with portfolio of small molecule drugs targeting viral diseases with major health problems and large international markets D-3 4
Slide 4: Near-term value creation milestones anticipated in late 2023
Near-term value creation milestones anticipated in late 2023 O1 Headline results from 3 human Phase 2 trials expected in coming weeks * Two HIV-1 Phase 2 trials anda SARS-CoV-2/COVID-19 Phase 2 trial + All three trials have been completed i.e. all patients have been recruited and completed dosing wi
Slide 5: Portfolio of Clinical & Preclinical Assets
Portfolio of Clinical & Preclinical Assets RESEARCH DEVELOPMEN j IND ENABLING/ mee Se 5 SESS) LEAD _ PHASE 1 SE 2 PHASE 3 OPTIMISATION PRECLINICAL Hivey BIT225 ar HIV-1 Next gen i= COVID-19 BIT225 i, GOMID-19 Next gen >> Lead cat optimisation = Dengue, Influenza & ones wads Peg Bietron
Slide 6: Recent Milestones & Achievements
Recent Milestones & Achievements @ Completed enrolment of two Phase 2 HIV-1 clinical trials that build on positive results in previous clinical studies @ Completed enrolment of Phase 2 COVID-19 clinical trial Based on demonstration that B!T225 prevents development of COVID-19 disease in an industry-
Slide 7: Why COVID?
Why COVID? Biotron Vulnerable populations remain at risk Current drugs have limitations due to dosing, interactions with other meds, etc Long COVID is a growing issue, affecting ~65 million people Strong international focus on ensuring preparedness for future pandemics Need to remain ahead of any em
Slide 8: COVID-19 Clinical Program
COVID-19 Clinical Program In 2022 BIT's lead antiviral drug was shown to: + Prevent COVID-19 * Reduce virus levels, and * Stop the cytokine storm in a relevant, robust, industry-recognised animal model of disease As BIT225 had been tested in humans for other viral diseases it could move quickly into
Slide 9: Why HIV-1?
Why HIV-1? 38.4m peopl globally livi HIV despite AR deaths/year from Al relat Biotron The increased prevalence of HIV-1 infections, % of patients on treatment due to improved disease awareness and the need for treatments to improve quality of life are expected to drive market growth to over US$SOb b
Slide 10: HIV-1 Clinical Program
HIV-1 Clinical Program Two Phase 2 HIV-1 clinical trials recently completed at sites in Sydney, Australia & in Thailand @ Results expected in coming weeks These trials build on 9 previous clinical trials of BIT225 that established safety and potential benefits in patients with HIV-1 and Hepatitis C
Slide 11: BIT225 Opportunity Summary
BIT225 Opportunity Summary BIT225 is an important clinical asset Previous positive clinical trial data have significantly de-risked the program Clear clinical development program designed to demonstrate to regulators and pharma how the drug may be used to improve health outcomes in combination with
Slide 12: Biotron
Biotron BIOTRON LIMITED (ASX:BIT) Michelle Miller Managing Director mmiller@biotron.com.au www.biotron.com.au +61 412313329